La Paz, Baja California Sur (OEM-Informex).- The State Deputy Commissioner against Sanitary Risks of the Ministry of Health, René Cota Avendaño announced that in Baja California Sur there are no detected cases of adverse reactions to the Dengvaxia vaccine against dengue.
He explained that the Dengvaxia dengue vaccine is not part of the basic list of vaccines of the Ministry of Health, but it is being applied to patients who request it in private clinics in the state, which is why there are recommendations for the application to be safe. “Fortunately, even “At the moment there have been no detected cases of adverse reactions in vaccinated patients in the five municipalities of the State.”
Lee: 19 cases of dengue and one death have been registered in BCS
URGED MEDICAL STAFF TO APPLY THE VACCINE SAFELY
Therefore, he urged that medical personnel who apply this type of vaccine apply it safely, respecting the population design of this biological that is recommended for patients between 9 and 45 years old, derived from the fact that the State Commission Against Sanitary Risks (COEPRIS) disseminates on its page an alert issued by the Federal Commission for the Protection against Health Risks (Cofepris).
On September 1, 2023, at the national level, general practitioners, nursing staff and pediatricians were informed of the Risk Notice regarding the use of the quadrivalent vaccine against dengue, Dengvaxia, after detecting that this biological was supplied to children under 9 years of age. This health authority communicates that Sanofi’s Dengvaxia vaccine is indicated only for the population from 9 years of age and up to 45 years of age.
Therefore, Cofepris urges health professionals that prior to the application of this biological, they must verify that the packaging is in Spanish, has a health record, batch number and expiration date, the latter data must match. With those shown in the vial with the lyophilized powder, it is suggested that medical personnel consult the attached instructions inside the packaging and review the technical sheet.
Subscribe here to the digital edition of El Sudcaliforniano
THE VACCINE TECHNICAL SHEET
The technical sheet for the Dengvaxia vaccine available at gob.mx/cofepris also specifies that the Dengvaxia vaccine must be applied under medical evaluation and supervision and reiterates that it should not be administered to children under 9 years of age, since it could represent a health risk. and health personnel and the population are urged not to purchase medications on social networks, sales platforms or other internet sites.
REPORTING COUNTERFEIT PRODUCTS
Since it could be a counterfeit product made with contaminated ingredients, of poor quality and lack the active ingredient, Cofepris calls for reporting internet sites or social media pages where medicines are offered through the Health Complaint hyperlink in order to protect people’s health, this federal commission maintains health surveillance actions to promptly identify counterfeit medications and will inform the population if new evidence is identified.
2023-09-11 07:31:29
#adverse #reactions #dengue #vaccine #BCS
